Key points are not available for this paper at this time.
This cohort study of patients with advanced melanoma treated with anti–programmed cell death 1 with or without ipilimumab assessed whether cutaneous toxic effects were associated with superior clinical outcomes.
Quach et al. (Thu,) studied this question.